Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

23 Nov 2024

Abstract excerpt

The RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CLpro), and papain-like protease (PLpro) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as promising therapeutic targets. Currently, all FDA-approved antiviral drugs against SARS-CoV-2 are RdRp or 3CLpro inhibitors. However, the mutations causing drug resistance have been observed in RdRp and 3CLpro from SARS-CoV-2, which makes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mosquito-borne diseases and control
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39580525
DOI: 10.1038/s41467-024-54462-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19PMID 39580525Read ↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitorsSemantic proximity Read ↗

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Semantic proximity Read ↗

Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like proteaseSemantic proximity Read ↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.Semantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

Existing Antiviral Options Against SARS-CoV-2 Replication in COVID-19 PatientsSemantic proximity Read ↗

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19Semantic proximity Read ↗

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoSemantic proximity Read ↗

Massive Virtual screening and evaluation of small molecule inhibitors of the Papain-like protease of SARS-CoV-2Semantic proximity Read ↗

Discovery of SARS-CoV-2 papain-like protease (PL <sup>pro</sup> ) inhibitors with efficacy in a murine infection modelSemantic proximity Read ↗

Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like proteaseSemantic proximity Read ↗

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.